Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;98(4):e400-e406.
doi: 10.1111/aos.14288. Epub 2019 Nov 17.

Patterns of morphologic alteration correlate with vision in diabetic macular oedema: a cross-sectional evaluation of patients using the SAVE II protocol

Matthias Bolz #  1   2 , Dominika Podkowinski #  1   2 , Josef Pretzl  1 , Anna-Sophie Mursch-Edlmayr  1   2 , Nikolaus Luft  3 , Michael Ring  1   4 ; SAVE Study Group
Affiliations
Free article

Patterns of morphologic alteration correlate with vision in diabetic macular oedema: a cross-sectional evaluation of patients using the SAVE II protocol

Matthias Bolz et al. Acta Ophthalmol. 2020 Jun.
Free article

Abstract

Purpose: We sought to describe and evaluate patients with clinically significant diabetic macular oedema (CSME) according to the improved SAVE II protocol and correlate findings with visual acuity and systemic parameters in the outpatient clinic for DR (diabetic retinopathy) management.

Methods: This was a cross-sectional case series study of patients with CSME, regardless of prior treatment. Visual acuity testing was performed according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol. Optical coherence tomography (OCT) and fluorescence angiography (FA) were performed. All imaging data were evaluated according to an improved version of the SAVE grading protocol for CSME (SAVE II). The main outcome measures were SAVE II oedema types and best-corrected visual acuity. Additional parameters of a blood sample (fasting glucose, haemoglobin A1c, serum creatinine, triglycerides, cholesterol, low-density lipoproteins, and high-density lipoproteins) were taken.

Results: In total, 66 eyes of 66 patients were included. The mean age of the patients was 64.9 ± 8.2 years. Two eyes were classified as SAVE oedema type 1, 19 eyes as SAVE oedema type 2, 28 eyes as SAVE oedema type 3, and 28 eyes as SAVE oedema type 4, respectively. Central retinal thickness and laboratory parameters were not significantly different between the groups. There was a statistically significant difference in ETDRS visual acuity between the SAVE groups 2 and 4 (p < 0.001) with lower vision in group 4. There was no statistically significant difference between oedema types 2 and 3 (p = 0.065) and oedema types 3 and 4 (p = 0.13).

Conclusion: There was a significant correlation between the four defined oedema types and visual acuity. Morphologic findings did not correlate with any of the evaluated blood parameters.

Keywords: SAVE II protocol; diabetic macular oedema; diabetic retinopathy; optical coherence tomography.

PubMed Disclaimer

References

    1. Avitabile T, Azzolini C, Bandello F et al. (2017): Aflibercept in the treatment of diabetic macular edema: A review and consensus paper. Eur J Ophthalmol 27: 627-639.
    1. Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA & Tuomi L (2015): Influence of glycosylated hemoglobin on the efficacy of ranibizumab for diabetic macular edema: A post hoc analysis of the RIDE/RISE trials. Ophthalmology 122: 1573-1579.
    1. Bolz M, Lammer J, Deak G, Pollreisz A, Mitsch C, Scholda C, Kundi M & Schmidt-Erfurth U (2014): SAVE: a grading protocol for clinically significant diabetic macular oedema based on optical coherence tomography and fluorescein angiography. Br J Ophthalmol 98: 1612-1617.
    1. Chylack LT Jr, Wolfe JK, Singer DM et al. (1993): The lens opacities classification system III. The longitudinal study of cataract study group. Arch Ophthalmol 111: 831-836.
    1. Das A, McGuire PG & Rangasamy S (2015): Diabetic macular edema: Pathophysiology and novel therapeutic targets. Ophthalmology 122: 1375-1394.

LinkOut - more resources